**Suppl 1**. Literature Review

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Study** | **Number of cases** | **Median age** | **M/F** | **Associated malignancy B-cell lymphoma (n)/T-/NK-cell lymphoma (n)** | **Fever** | **Hepatospleenomegaly** | **Cytopenias** | **Hypertriglyyceridemia** | **Hyperferretinemia** | **Hypofibrinogen** | **NK-cell activity/soluble CD25/IL-2** | **Hemophagocytosis** | **EBV ISH +** | **NHL/HLH therapy** | **Outcome/status** | **Median survival from HLH diagnosis** |
| 1 | Han et al, 2007 [10] | 29 | 46 ( 9 - 87) | 16:13 | 5/24 | 29 (100%) | 27 (93.1%) | 25 (86.2%) | NA | 13 (92.9%) | 15 (57.7%) | NA | NA | 13 (68.4%) | 23 | CR (4), PR (3) | 36 days |
| 2 | Jiang et al, 2016 [6] | 41 | 44 (24.5 - 54.0) | 28:13 | 29/12 | 41 (100%) | 36 (87.8%) | NA | NA | NA | NA | 40 (97.5%) | 32 (78%) | NA | NA | Dead (26) | 120 days |
| 3 | Li et al, 2014 [11] | 16 | 48.5 (15 - 70) | 10:6 | 1/15 | 16 (100%) | 13 (81.3%) | 16 (100%) | 10 (62.5%) | 16 (100%) | 15 (93.8%) | NA | 9 (56.3%) | 7 (43.8%) | 13 (81%) | CR (1), PR (2), dead (15) | 37 days |
| 4 | Yu et al, 2013 [8] | 30 | 51 (21 - 77) | 13:17 | 13/17 | NA | 26 (86%) | 24 (80%) | NA | NA | NA | NA | 20 (66%) | 9 (30%) | 30 (100%) | CR (9), PR (2), dead (23) | 231 days |
| 5 | Cattaneo et al, 2016 [9] | 24 | NA | NA | 10/14 | NA | NA | NA | NA | 24 (100%) | NA | NA | NA | 10 (41%) | 24 (100%) | CR (9) | 87 days |
| 6 | Parikh et al, 2014 [7] | 32 | 54 (18 - 87) | 22:10 | 9/19 | NA | NA | NA | 9 (43%) | 25 (100%) | 30 (55%) | NA | NA | NA | 25 (84%) | NA | 42 days |

NA: not available; CR: complete remission; PR: partial remission.

6. Jiang T, Ding X, Lu W. The prognostic significance of Beta2 microglobulin in patients with hemophagocytic lymphohistiocytosis. Dis Markers. 2016;2016:1523959.  
doi:10.1155/2016/1523959  
PubMed PMID:27110054

7. Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89(4):484-492.  
doi:10.1016/j.mayocp.2013.12.012  
PubMed PMID:24581757

8. Yu JT, Wang CY, Yang Y, Wang RC, Chang KH, Hwang WL, Teng CL. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Ann Hematol. 2013;92(11):1529-1536.  
doi:10.1007/s00277-013-1784-3  
PubMed PMID:23700280

9. Cattaneo C, Oberti M, Skert C, Passi A, Farina M, Re A, Tozzi P, et al. Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients. Hematol Oncol. 2017;35(4):828-834.  
doi:10.1002/hon.2314  
PubMed PMID:27255829

10. Han AR, Lee HR, Park BB, Hwang IG, Park S, Lee SC, Kim K, et al. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol. 2007;86(7):493-498.  
doi:10.1007/s00277-007-0278-6  
PubMed PMID:17347847

11. Li F, Li P, Zhang R, Yang G, Ji D, Huang X, Xu Q, et al. Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. Med Oncol. 2014;31(4):902.  
doi:10.1007/s12032-014-0902-y  
PubMed PMID:24610542